Investigational — not approved anywhere
Vatiquinone
What it isVatiquinone (formerly EPI-743) is an investigational oral 15-lipoxygenase inhibitor that modulates oxidative stress and mitochondrial energy metabolism.
Why this oneIt is being developed for Friedreich ataxia, where it aims to slow neurologic disease progression.
What limits itThe Phase 3 MOVE-FA trial missed its primary endpoint (change in mFARS) despite benefit on some secondary measures, and it is not FDA approved.
NO BOXED WARNINGS
Principal riskNo FDA boxed warning (investigational).
Classes and tags
Clinical profile
Mechanism of action: Vatiquinone ballicule
